Drug Trial Radar · NCT07160244
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6,000
Planned (sponsor's estimate)
Start
Aug 25, 2025
Primary completion
Nov 6, 2028
Study completion Mar 2, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 day, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their babies. This study is seeking healthy pregnant participants: * aged 49 or younger who can join. * between 24 and 36 weeks of gestation ("Gestational age" is a medical term used to describe how far along your pregnancy is) * had a fetal ultrasound examination performed with no major fetal abnormalities observed * documented negative for HIV, syphilis and Hepatitis B All participants in this study will receive only 1 shot in an arm. This could either be a group B streptococcus 6-valent polysaccharide conjugate vaccine (GBS6) or placebo. Placebo is an inactive substance used in the study for comparison purposes; in this study, the placebo injection will be saline (saltwater). The pregnant participants may take part in this study for a maximum of 14 months (6 months after delivery) , and their babies for about 12 months after they are born. The pregnant participants will need to visit the research site at least 3 to 4 times with some visits permitted to occur over the telephone. A subset of infants will be asked to take part in the study for up to 19 months. The subset will receive diphtheria toxoid-containing vaccine and/or pneumococcal vaccine following each country's standard immunization plan and have blood drawn 1 month after completion of the primary and/or toddler (booster) doses.
Conditions
- Healthy
Interventions
Multivalent Group B streptococcus vaccineBiological
Multivalent Group B streptococcus vaccine
PlaceboBiological
Saline Control
Infanrix hexaBiological
Vaccine administered in a subset of infant participants as per the national immunization schedule
Prevenar 20Biological
Vaccine administered in a subset of infant participants as per the national immunization schedule
PediarixBiological
Vaccine administered in a subset of infant participants as per the national immunization schedule
Prevnar 20Biological
Vaccine administered in a subset of infant participants as per the national immunization schedule
InfanrixBiological
Vaccine administered in a subset of infant participants as per the national immunization schedule
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of maternal participants reporting prespecified local reactions within 7 days following study interventionTime frame: Within 7 days
- The proportion of maternal participants reporting prespecified systemic events within 7 days following study interventionTime frame: Within 7 days
- The proportion of maternal participants reporting adverse events (AEs) through 1 month following study interventionTime frame: 1 month
- The proportion of maternal participants reporting serious adverse events (SAEs) through 6 months after deliveryTime frame: 6 months after delivery
- The proportion of maternal participants reporting medically attended adverse events (MAAEs) through 6 months after deliveryTime frame: 6 months after delivery
- The proportion of maternal participants reporting adverse events of special interest (AESIs) through 6 months after delivery.Time frame: 6 months after delivery
- The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting adverse events (AEs) from birth through 1 month of ageTime frame: Birth to 1 month of age
- The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting serious adverse events (SAEs) from birth through end of the studyTime frame: Through study completion, at least 1 year
- The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting medically attended adverse events (MAAEs) from birth through 6 months of ageTime frame: Birth to 6 months of age
- The proportion of infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy reporting adverse events of special interest (AESIs) from birth through end of studyTime frame: Through study completion, at least 1 year
- To measure the relative risk reduction in the proportion of infant participants at birth with GBS serotype-specific IgG antibody concentrations below predefined serotype-specific GBS late onset disease thresholds in the GBS6 group to the placebo groupTime frame: Birth
- To measure the relative risk reduction in the proportion of infant participants at birth with GBS serotype-specific IgG antibody concentrations below predefined serotype-specific GBS early onset disease thresholds in the GBS6 group to the placebo groupTime frame: Birth
- To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS late onset disease based on serotype specific anti-CPS IgG concentrations measured in infants at birth.Time frame: Birth
- To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS early onset disease based on serotype specific anti-CPS IgG concentrations measured in infants at birth.Time frame: Birth
Locations
219 sites in 15 countries. Site status is shown where the registry gives one.
Center for Research in Women's Health
Birmingham, Alabama · Recruiting
Children's of Alabama
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham - School of Medicine
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham Women & Infants Center
Birmingham, Alabama · Recruiting
SEC Clinical Research
Dothan, Alabama · Recruiting
USA Health Allen Cox Building
Mobile, Alabama · Recruiting
USA Health Children's and Women's Hospital
Mobile, Alabama · Recruiting
USA Health Mitchell Cancer Institute
Mobile, Alabama · Recruiting
USA Health Strada Patient Care Center
Mobile, Alabama · Recruiting
ClinMed
Phoenix, Arizona · Recruiting
Valleywise Comprehensive Health Center Women's Clinic
Phoenix, Arizona · Recruiting
Valleywise Health Medical Center
Phoenix, Arizona · Recruiting
Northwest Women's Center
Tucson, Arizona · Recruiting
Genesis OB/GYN
Tucson, Arizona · Recruiting
Eclipse Clinical Research
Tucson, Arizona · Recruiting
Antelope Valley Medical Center
Lancaster, California · Recruiting
Chemidox Clinical Trials
Lancaster, California · Recruiting
Loma Linda University Children's Hospital
Loma Linda, California · Recruiting
Loma Linda University Health System
Loma Linda, California · Recruiting
Loma Linda University Pediatrics Clinic
Loma Linda, California · Recruiting
Lucile Packard Children's Hospital
Palo Alto, California · Recruiting
Stanford Obstetrics Clinic
Palo Alto, California · Recruiting
Stanford University Medical Center
Palo Alto, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
Anschutz Health Sciences Building
Aurora, Colorado · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
CU Research Pharmacy
Aurora, Colorado · Recruiting
University of Colorado AO1
Aurora, Colorado · Recruiting
University of Colorado Hospital Outpatient Pavilion
Aurora, Colorado · Recruiting
University of Colorado Hospital
Aurora, Colorado · Recruiting
University of Colorado Research II Building
Aurora, Colorado · Recruiting
South Florida Clinical Research Institute - Margate
Margate, Florida · Recruiting
Citadelle Clinical Research
North Miami Beach, Florida · Recruiting
Emerald Coast OBGYN Clinical Research
Panama City, Florida · Recruiting
Emerald Coast Pediatrics
Panama City, Florida · Recruiting
HCA Florida Gulf Coast Hospital
Panama City, Florida · Recruiting
ASR, LLC
Boise, Idaho · Recruiting
Express Lab
Garden City, Idaho · Recruiting
Clinical Research Prime
Idaho Falls, Idaho · Recruiting
Eastern Idaho Regional Medical Center
Idaho Falls, Idaho · Recruiting
Showing 40 of 219 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.